文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

靶向替代补体通路因子D可减缓年龄相关性黄斑变性继发的地图样萎缩进展

Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
PubMed 文献 · Sci Transl Med · 2017-01-01

MAHALO 2期多中心随机对照试验评估玻璃体腔注射 lampalizumab(靶向补体因子D)治疗年龄相关性黄斑变性继发地图样萎缩的疗效与安全性。每月给药组较假手术对照组病灶面积进展减少20%(80%CI 4%~37%);在补体因子I风险等位基因携带者亚组中,每月治疗组较假手术对照组减少44%(95%CI 15%~73%)。研究表明对替代补体通路的治疗性靶向可能对地图样萎缩患者有潜在治疗效应。

要点

  • 每月玻璃体腔注射lampalizumab较假手术对照组使地图样萎缩病灶面积进展减少20%(80%CI 4%~37%)。
  • 在CFI风险等位基因携带者亚组(占分析患者57%)中,每月治疗组较假手术对照组减少44%(95%CI 15%~73%)。
  • MAHALO 2期试验达到主要疗效终点且安全性可接受,支持靶向替代补体通路治疗AMD。

核心结论

  • MAHALO研究显示lampalizumab对地图样萎缩患者有潜在治疗效应,并支持将替代补体通路作为AMD发病机制的治疗靶点。

研究设计与样本

  • MAHALO为多中心、随机、对照2期临床试验,纳入年龄相关性黄斑变性继发地图样萎缩患者,每月玻璃体腔注射lampalizumab组n=42、每两月注射组n=41、假手术对照组n=40。
  • 主要终点为基线至第18个月经眼底自发荧光测量的病灶面积平均变化,并分析特定AMD相关基因多态性。

主要发现

  • 每月lampalizumab治疗组较假手术对照组病灶面积进展减少20%(80%CI 4%~37%)。
  • 在CFI风险等位基因携带者亚组(占分析患者57%)中,每月治疗组较假手术对照组地图样萎缩面积进展减少44%(95%CI 15%~73%)。
  • MAHALO研究达到主要疗效终点,且安全性可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Geographic atrophy is an advanced form of age-related macular degeneration (AMD) and a leading cause of vision loss for which there are no approved treatments. Genetic studies in AMD patients have implicated dysregulation of the alternative complement pathway in the pathogenesis of geographic atrophy. Lampalizumab is a potential therapeutic that targets complement factor D, a pivotal activator of the alternative complement pathway. The MAHALO phase 2 clinical trial was a multicenter, randomized, controlled study that evaluated lampalizumab administered by intravitreal injection monthly (n = 42) and every other month (n = 41) versus sham control (n = 40) in patients with geographic atrophy secondary to AMD. The primary endpoint was the mean change in lesion area from baseline to month 18 as measured by fundus autofluorescence. Specific AMD-associated genetic polymorphisms were also analyzed. The MAHALO study met its primary efficacy endpoint with an acceptable safety profile; monthly lampalizumab treatment demonstrated a 20% reduction in lesion area progression versus sham control [80% confidence interval (CI), 4 to 37%]. A more substantial monthly treatment benefit of 44% reduction in geographic atrophy area progression versus sham control (95% CI, 15 to 73%) was observed in a subgroup of complement factor I (CFI) risk-allele carriers (57% of the patients analyzed were CFI risk-allele carriers). The MAHALO study shows a potential treatment effect in patients with geographic atrophy and supports therapeutic targeting of the alternative complement pathway for treating AMD pathogenesis.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017. PMID: 28637922. doi:10.1126/scitranslmed.aaf1443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。